

Guidelines on wound assessment methods and cell characterization

Project: PROMOS – Strengthening the biomedical ecosystem

WP3.1-Deliverable 2: Achievements by ICGEB and MUI under PROMOS WP3 and guidelines for wound assessment modalities and cell characterization in the development of cell therapies based on the Stromal Vascular Function (SVF) of the adipose tissue to promote the healing of chronic wounds.

Abstract

In Deliverable 2 wird der im Arbeitspaket 3 (WP3) von PROMOS entwickelte methodische und experimentelle Rahmen zusammengefasst. Dieser zielt darauf ab, Strategien zur Wundbeurteilung und die Charakterisierung der stromalen vaskulären Fraktion (SVF) im Kontext regenerativer, zellbasierter Therapien zu standardisieren. Dabei wurden klinische Instrumente zur Bewertung der Wundheilung untersucht und die Notwendigkeit harmonisierter und reproduzierbarer Ergebnismaße in Studien mit SVF-basierten Interventionen hervorgehoben. Durch die Integration strukturierter klinischer Skalen (z. B. PUSH-, BWAT- und DFU-Klassifikationen) mit quantitativen Messungen wie der Wundheilungsrate (WHR), digitaler Planimetrie und nicht-invasiven Technologien (OCT, DNIRS, Bioimpedanz, Thermografie) wird eine multidimensionale und objektive Bewertungsplattform geschaffen. Ein solcher standardisierter Rahmen ist unerlässlich, um die Vergleichbarkeit zwischen Studien zu gewährleisten und eine robuste Bewertung der therapeutischen Wirksamkeit zu ermöglichen. Wir haben die Kulturbedingungen für die SVF-Expansion unter GMP-konformen Bedingungen optimiert. Unter den getesteten Medien zeigte HEM eine überlegene Fähigkeit zur Expansion von EC und FAP, ohne die Profile der Schlüsselmarker zu verändern. Diese Ergebnisse stützen die Auswahl von HEM als bevorzugtes Medium für die Expansion von SVF in klinischer Qualität und tragen zur Reproduzierbarkeit und translationalen Bereitschaft bei. Wir haben verschiedene Methoden

PROMOS

zur Entnahme von Fettgewebe verglichen und festgestellt, dass das aus einer Liposuktion gewonnene SVF hinsichtlich der Endothelzellen (EC) und FAP-Zellen phänotypisch mit dem en-bloc gewonnenen SVF vergleichbar ist. Aufgrund ihrer geringeren Invasivität, besseren Skalierbarkeit und Kompatibilität mit geschlossenen Systemen stellt die Liposuktion einen klinisch durchführbaren und ethisch vertretbaren Ansatz für autologe Anwendungen dar. Die multiparametrische Durchflusszytometrie-Profilierung von 59 Spendern ergab darüber hinaus, dass die SVF-Zusammensetzung durch patientenspezifische Variablen wie Alter und Gewichtsverlustgeschichte beeinflusst wird. Diese Daten deuten darauf hin, dass Spendermerkmale das regenerative Potenzial von ASC-Subpopulationen, insbesondere von proangiogenen und CD26⁺/CD55⁺-Populationen, modulieren können. Dies untermauert das Konzept der Spender-Stratifizierung in zukünftigen therapeutischen Protokollen. Wir untersuchten außerdem die Zellvermehrung und Kryokonservierung. Dabei zeigte sich, dass die Vermehrung bekannte Verschiebungen in der Expression von Oberflächenmarkern hervorruft (z. B. eine Verringerung von CD34), wesentliche mesenchymale Eigenschaften jedoch weitgehend erhalten bleiben. Die Kryokonservierung, einschließlich der Langzeitlagerung, bewahrt die Lebensfähigkeit und das funktionelle Potenzial, sofern kontrollierte Protokolle angewendet werden. Dies untermauert die Durchführbarkeit des SVF-Biobankings im Rahmen von PROMOS. Insgesamt schafft Deliverable 2 eine standardisierte, evidenzbasierte Plattform für die Wundbeurteilung und die Charakterisierung von SVF und stärkt somit das translationale Potenzial von SVF-basierten regenerativen Therapien. Auf der Grundlage dieser Erkenntnisse ergeben sich mehrere strategische Ausrichtungen für die künftige klinische Umsetzung.

Part 1

1. Wound healing assessment

Effective wound assessment is critical for managing chronic ulcers, enabling clinicians to establish baseline severity, monitor healing progression, and tailor treatment strategies. Chronic wounds, full-thickness skin lesions that fail to heal within four weeks, typically remain stalled in the inflammatory phase. They are often associated with vascular, diabetic, and pressure ulcers, and exacerbated by comorbidities such as diabetes and peripheral arterial disease, particularly in elderly patients. Despite growing interest in cell-based therapies, standardized tools for objective wound evaluation remain limited. To address this gap, we reviewed validated assessment methods currently used in clinical practice and evaluated their applicability for monitoring outcomes in cell-based treatments.

1.2 Clinical evaluation and assessment scales

Wound assessment relies on multiple parameters, including size (length × width), depth, wound edges, undermining, necrotic tissue type and amount, exudate characteristics, surrounding skin color, peripheral edema, induration, granulation tissue, and epithelialization. Additional measures such as thermometry, oxygen saturation, and blood perfusion provide further insight into tissue viability.

Size measurement

Manual measurement with a sterile ruler remains the simplest and most widely adopted method. However, digital imaging has become increasingly important, offering standardized photographic documentation for longitudinal analysis. High-quality wound photography requires strict standardization: the camera should be positioned perpendicular to the wound, lighting must be diffuse to avoid glare, and a reference scale (e.g., ruler) should be included.

PROMOS

Dedicated software can then convert pixel counts into surface area (cm²), ensuring reproducible quantification.

Wound Healing Rate

The Wound Healing Rate (WHR) or Ulcer Healing Rate (UHR) provides a quantitative measure of re-epithelialization, calculated as:

$$(A_i - A_f) / A_i (A_i - A_f) / A_i$$

where A_i is the initial wound area and A_f the final measurement. WHR values range from –1.0 to 1.0 or as percentage closure, with 100% indicating complete healing. This metric is widely used in preclinical studies and offers a standardized approach for tracking progress ¹.

Standardized Tools

PUSH

Developed by the National Pressure Ulcer Advisory Panel, PUSH assesses surface area, exudate amount, and tissue type. It demonstrates strong validity, high inter-rater reliability, and sensitivity to clinical change ³⁻⁵.

BWAT

The Bates-Jensen Wound Assessment Tool evaluates 13 wound characteristics, providing a comprehensive profile across chronic wound types. While more time-intensive than PUSH, BWAT is widely used in clinical trials and offers robust outcome measures ⁶⁻¹¹.

Diabetic Foot Ulcer Scales

In the context of Diabetic Foot Ulcers (DFU), multiple classification and severity systems have been proposed. Tools such as the Wagner Scale, University of Texas (UT) system, SAD, and PEDIS classifications provide structured frameworks for grading ulcer severity, infection status, and ischemia, aiding treatment planning and prognostic assessment ¹²⁻¹⁹.

PROMOS

1.3 Biophysical assessment

Non-invasive technologies complement clinical evaluation by providing objective physiological data:

- **Optical Coherence Tomography (OCT):** Offers high-resolution imaging comparable to histology, enabling assessment of inflammation and tissue remodeling without biopsy²⁰.
- **Diffuse Near-Infrared Spectroscopy (DNIRS):** Measures oxygenation trends in the wound bed, predicting healing trajectories²¹.
- **Bioimpedance:** Reflects tissue composition and hydration, serving as a marker for wound progression²².
- **Thermography:** Captures temperature gradients to calculate a thermal index, correlating with inflammatory activity and healing potential²³.

1.4 Histopathological analysis

When deeper insight is required, biopsy followed by hematoxylin and eosin staining remains the gold standard for characterizing cellular composition and excluding malignant transformation. This approach identifies key immune cell populations, such as M1 pro-inflammatory and M2 anti-inflammatory macrophages, which influence healing dynamics¹.

2. Selection of culture media for SVF expansion

Standardizing culture conditions is essential for ensuring reproducibility and regulatory compliance in cell-based therapies. Within the PROMOS framework, ICGEB focused on optimizing the expansion of Stromal Vascular Fraction (SVF) cells derived from human adipose tissue. These cells include endothelial cells (ECs) and fibro-adipogenic progenitors (FAPs), both critical for tissue regeneration and wound healing.

PROMOS

Comparative Analysis of Culture Media

We evaluated three GMP-grade media to identify the most effective formulation for expanding SVF-derived cells:

- **Human Endothelial Medium (HEM)** – specifically designed for endothelial cell culture.
- **DMEM/F12** – a widely used medium for primary cells and cell lines.
- **EGM-2** – commonly employed for endothelial cell expansion in research settings.

Performance Assessment

Cell expansion was assessed using immunofluorescence and flow cytometry:

- **Endothelial Cells:** HEM demonstrated superior performance, achieving the highest CD31+ area (5.7%) and ERG+ nuclei count (15.2%), compared to DMEM/F12 (1.5%, 5.2%) and EGM-2 (4.4%, 8.3%).
- **Smooth Muscle Cells:** No significant differences were observed among media for α -SMA expression.
- **Flow Cytometry** confirmed that HEM promotes robust expansion of ECs (CD45–CD31+CD146+CD34+) and FAPs (CD45–CD146–CD31–CD34+), supporting its suitability for clinical-grade cell production.

Implications

Selecting HEM as the preferred medium ensures optimal yield and quality of regenerative cell populations under GMP-compliant conditions. This standardization is a critical step toward translating SVF-based therapies into clinical trials, improving consistency and therapeutic outcomes.

PROMOS

3. Methods of adipose tissue collection and SVF extraction

Adipose tissue is a rich source of regenerative cells, particularly the Stromal Vascular Fraction (SVF), which contains endothelial cells, fibro-adipogenic progenitors, and other supportive cell types. Standardizing collection and processing methods is essential to ensure cell viability, reproducibility, and compliance with clinical-grade requirements.

3.1 Evolution of Collection Techniques

Historically, adipose tissue was harvested via en bloc excision ²⁴⁻²⁶, primarily for reconstructive purposes. While this approach preserves tissue architecture and minimizes shear stress, it is invasive, associated with higher morbidity, and unsuitable for large-scale or minimally invasive applications. Modern practice favors liposuction-based techniques, which are less invasive, scalable, and compatible with closed-system processing workflows.

3.2 Current Harvesting Methods

Three main techniques dominate clinical and experimental practice:

Coleman technique

The Coleman method involves gentle manual aspiration using syringes without suction, followed by reinjection in small aliquots ²⁴.

Advantages:

- High cell viability due to minimal mechanical trauma.
- Lower risk of complications such as hematomas or fibrosis.
- Faster recovery for patients.

Limitations:

- Labor-intensive and time-consuming.

PROMOS

- Limited scalability for large-volume harvesting.
- Operator-dependent reproducibility.

Power-Assisted Liposuction (PAL) - Microaire system

PAL uses an electrically driven handpiece that imparts rapid reciprocating motion to the cannula (4,000–5,000 cycles/min), reducing surgeon fatigue and operative time ²⁷.

Advantages:

- Efficient for large-volume harvesting.
- Improved cannula advancement in fibrous tissue.
- Lower postoperative discomfort compared to manual methods.

Considerations:

- Aggressive settings may increase tissue trauma and risk of hematoma or contour irregularities.
- For regenerative applications, conservative suction and cannula design are recommended to preserve delicate cell populations.

Puregraft Closed Filtration System

Puregraft provides a sterile, single-use filtration chamber for washing and purifying lipoaspirate ²⁸.

Advantages:

- Removes blood, tumescent fluid, and free lipids without centrifugation.
- Minimizes shear stress, preserving cell viability.
- Closed system reduces contamination risk and ensures regulatory compliance.

PROMOS

Limitations:

- Higher per-procedure cost due to disposable kits.
- Limited capacity (250–850 mL), making it more suitable for small- to medium-volume procedures.

3.3 SVF Extraction and Processing

Following collection, adipose tissue or lipoaspirate undergoes enzymatic digestion and mechanical dissociation:

- Tissue is rinsed with calcium- and bicarbonate-free Hank's solution (CBFHH) and minced.
- Digestion is performed using collagenase and DNase II in a buffered solution, followed by neutralization in endothelial medium supplemented with platelet lysate.
- Sequential centrifugation and filtration (70 μm strainer) yield a purified SVF cell suspension.
- Cells are plated at a density of 5×10^4 cells/cm² for expansion.

This standardized workflow ensures high cell recovery and viability, supporting downstream applications in regenerative medicine.

3.4 In Vitro Comparison of Lipoaspiration and En Bloc Tissue Methods

Given the superior clinical feasibility of lipoaspirate as a starting material for autologous cell therapy, ICGEB evaluated the expansion potential of Stromal Vascular Fraction (SVF) cells derived from adipose tissue collected using different liposuction techniques, compared to the traditional en bloc excision method.

PROMOS

Comparative Analysis

Flow cytometry performed on freshly isolated cells revealed no significant differences in endothelial cell (EC) populations across harvesting methods:

- Manual: 0.9%
- PureGraft: 0.5%
- MicroAire: 0.9%
- En bloc: 3.8%

Similarly, fibro-adipogenic progenitor (FAP) populations were comparable:

- Manual: 24.1%
- PureGraft: 23.6%
- MicroAire: 29.2%
- En bloc: 42.9%

Immunofluorescence Findings

Immunofluorescence confirmed consistent expression of key markers across all methods:

- **CD31** (endothelial marker): Manual 4.8%, PureGraft 8.7%, MicroAire 5.7%, En bloc 5.1%
- **ERG** (endothelial nuclear marker): Manual 23.6%, PureGraft 9.9%, MicroAire 15.5%, En bloc 21.6%
- **α -SMA** (smooth muscle marker): Manual 3.6%, PureGraft 5.3%, MicroAire 3.5%, En bloc 1.7%

These results indicate that the choice of adipose tissue harvesting method, whether lipoaspiration or en bloc excision, does not significantly impact SVF composition or marker expression. Consequently, lipoaspirate represents a clinically viable and less invasive alternative for SVF isolation, supporting its use in regenerative applications.

Part 2

1. Outline of the different marker

The stromal vascular fraction (SVF) of adipose tissue comprises a heterogeneous mixture of hematopoietic, endothelial, and mesenchymal cell populations, including adipose-derived stem/stromal cells (ASCs). Within this compartment, multiparameter flow cytometry enables the identification of cellular subsets based on surface marker expression profiles, allowing a refined characterization of present cell populations. While hematopoietic cells are commonly identified by CD45 expression, endothelial cells typically express CD3. In contrary, ASCs must lack expression of hematopoietic and endothelial markers, but express CD34. According to the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT), ASCs are recommended to be identified by a surface marker profile including CD34, CD73, CD44, CD90, and CD105.

In addition, ASCs must be plastic-adherent in standard culture conditions and display in vitro differentiation capacity toward adipogenic, chondrogenic, and osteogenic lineages²⁹.

Recent studies have described several distinct ASC subpopulations in SVF³⁰. These ASC subsets differ in their regenerative potential; however, their precise phenotypic definition and functional relevance, particularly in the context of wound healing and therapeutic applications, remain only partially understood and are the focus of ongoing investigation.

CD55⁺CD26⁺ double-positive ASCs represent a functionally enriched subset within human adipose tissue that appears especially well suited to promote wound healing. These cells retain a typical mesenchymal immunophenotype but exhibit a distinct transcriptional and secretory profile compared with CD55⁻ and/or CD26⁻ ASC fractions, including increased expression of genes associated with angiogenesis, extracellular matrix remodeling, and immune modulation. Functionally, CD55⁺CD26⁺ ASCs enhance wound closure by acting on several key phases of repair: they promote early angiogenesis, accelerate re-epithelialization, and support deposition and remodeling of granulation tissue. In murine skin-wounding models, transplantation of this subset, or SVF products enriched for CD55⁺CD26⁺ (DPP4) ASCs,

PROMOS

results in faster wound contraction, thicker and better organized neoderms, and increased vascular density compared with unfractionated ASCs, effects that correlate with elevated local levels of VEGF and other pro-regenerative mediators^{31,32}. CD55 is thought to contribute by protecting transplanted cells and surrounding tissues from complement-mediated damage and by modulating the inflammatory milieu to favor a pro-resolving macrophage phenotype, thereby facilitating the transition from inflammation to proliferation (PMID: 37357314). CD26/DPP4, in turn, modulates the bioavailability of chemokines and growth factors involved in cell recruitment, angiogenesis, and matrix turnover; altered CD26 activity within the wound bed has been linked to changes in revascularization, fibroblast behavior, and overall wound closure dynamics³³⁻³⁵. Together, coexpression of CD55 and CD26 defines an ASC subset whose combined complement-regulatory and protease activities appear to fine-tune the inflammatory and angiogenic environment, thereby potentiating the intrinsic pro-regenerative functions of ASCs in cutaneous wound healing.

CD55 expression has also been associated with augmented differentiation capacity, supporting the concept that complement-regulatory molecules expressed on ASCs may stratify subpopulations with distinct lineage commitment profiles and trophic properties³⁶.

CD26 marks ASC subsets with altered proliferative and differentiation behavior and has been implicated in the regulation of cellular senescence^{37,38}. Emerging evidence links CD26⁺ ASCs to obesity-associated alterations in adipose tissue biology. In obese mice, the proportion and phenotype of CD26⁺ ASCs within the SVF are decreased compared with lean controls³⁹.

Additional marker combinations further refine the functional heterogeneity of ASCs and related SVF populations. For example, CD140a⁺ ASCs stratified by high or low CD9 expression have been associated with fibrotic remodeling, suggesting that tetraspanin–integrin signaling modules may identify progenitor pools that either promote or restrain extracellular matrix deposition⁴⁰.

In parallel, endothelial-committed fractions within the SVF, defined by CD31⁺CD146⁺ expression, contribute significantly to wound repair through their angiogenic capacity and paracrine support of surrounding cells⁴¹.

PROMOS

Collectively, these observations illustrate that specific marker constellations such as CD55⁺CD26⁺, CD26⁺, CD140a⁺CD9^{high/low}, and CD31⁺CD146⁺ can be used to functionally describe SVF and ASC populations with respect to differentiation potential, fibrotic propensity, and pro-regenerative efficacy. Nevertheless, the molecular mechanisms linking surface phenotype to functional output remain incompletely defined. Systematic studies integrating high-resolution phenotypic profiling with standardized in vitro and in vivo functional assays are still required to translate these findings into robust, marker-guided cell selection strategies for wound healing and other therapeutic applications.

Within the PROMOS framework, MUI aimed to profile SVF and its cellular composition to assess cell types present and evaluate donor potential for wound healing therapies. The work was done applying a multi-gate flow cytometry analysis for cell surface markers of endothelial cells (CD45⁻/CD31⁺), hematopoietic cells (CD45⁺), and ASCs (CD45⁻/CD31⁻/CD90⁺/CD34⁺) as well as ASC subtypes (CD26⁺, CD55⁺, CD146⁺, CD9⁺, CD140a⁺). Data from 59 patients were further analyzed according to patient characteristics and compared by sex (female vs. male), method of weight loss, smoking status (non-smokers vs. smokers), and subjected to linear regression analyses with respect to age, extent of weight loss (%), and body mass index (BMI) at the time of abdominoplasty.

Age positively correlated with higher hematopoietic cells and certain ASC subtypes like CD26⁺ and CD146⁺. Additionally, we found that weight loss method is associated with pro-angiogenic ASC markers.

These results indicate patient factors may affect ASC regenerative quality, warranting further donor optimization research.

2. Impact of SVF expansion on marker expression

In vitro expansion of SVF cells leads to notable shifts in surface marker expression, particularly among adipose-derived stem cells (ASCs). In general, it is well known that ASCs retain the expression of many markers, including CD73⁺, CD105⁺ and CD90⁺, while CD34⁺ is quickly lost over time in culture. The loss of CD34 expression may reflect ASC commitment to

PROMOS

differentiation, though other researchers contend that variable ex vivo CD34 levels arise from suboptimal culture conditions lacking the factors needed to sustain in vivo expression ⁴².

Initial adherence selects for fibroblast-like ASCs, with proliferation rates being influenced by culture conditions, donor specificity and seeding density. Media choice, such as DMEM with FBS versus endothelial media like EGM-2, modulates subtype selection and surface marker expression profiles (e.g., higher perivascular markers in DMEM).

3. Impact of cryopreservation

Cryopreservation of stromal vascular fraction (SVF) enables long-term storage of adipose-derived cell populations for repeated or delayed cell culture or analysis. SVF is typically frozen in a cryoprotective medium containing serum (e.g., FBS or human serum) and a permeating cryoprotectant such as dimethyl sulfoxide (DMSO), followed by controlled-rate or stepwise cooling to $-80\text{ }^{\circ}\text{C}$ and subsequent transfer to liquid nitrogen for long-term storage.

It has been shown that cryopreservation typically decreases the number of viable SVF cells but mainly affecting hematopoietic CD45⁺ cells. However, the remaining cells retain adhesive, proliferative properties, and colony-forming ability similar to fresh samples and therefore also expendable in vitro ⁴³. Consistent with expectations and prior reports, cryopreserved cells required slightly longer to reach confluence, likely attributable to DMSO exposure ⁴³. SVF stem cell potency remains largely intact post-cryopreservation, as shown by comparable surface marker expression (e.g., CD34⁺, CD105⁺, CD73⁺, CD29⁺), and adipogenic and osteopogenic differentiation.

When comparing short- (1-2 months) versus long-term (12-13 years) cryopreservation, it was found that the extended cryopreservation reduces stemness but retains partial wound-healing potential ⁴⁴.

Within the PROMOS project, MUI utilized an extensive cell bank comprising cryopreserved SVF samples from over 55 patients undergoing elective abdominoplasty between September 2019 and December 2025. Flow cytometry analyses yielded critical insights into SVF composition and post-thaw cell viability; Although cryopreservation typically is expected to result in reduced viable nucleated cell counts, using a simple viability dye, no correlation was

PROMOS

observed between storage duration and viability. The percentage of viable cells remained stable regardless of extended cryostorage time.

These findings, along with current evidence, indicate that cryopreserved SVF retains sufficient functional properties for clinical use - when appropriate protocols and controlled conditions are applied. Thus, SVF banking remains a valid option for preserving its therapeutic potential over longer storage periods. In parallel, freezing adipose tissue as an intact graft is technically feasible and has been clinically applied in some settings; however, it is associated with more variable cell survival and graft retention compared to isolated SVF, suggesting less predictable regenerative performance ⁴⁵.

Part 3

1. Conclusion and Perspective

This Deliverable 2 summarizes the methodological and experimental framework established within WP3 of PROMOS to standardize wound assessment strategies and stromal vascular fraction (SVF) characterization in the context of regenerative cell-based therapies.

We reviewed clinical tools for wound healing evaluation, highlighting the need for harmonized and reproducible outcome measures in studies involving SVF-based interventions. The integration of structured clinical scales (e.g., PUSH, BWAT, DFU classifications) with quantitative measurements such as wound healing rate (WHR), digital planimetry, and non-invasive technologies (OCT, DNIRS, bioimpedance, thermography) provides a multidimensional and objective assessment platform. Such a standardized framework is essential to enable cross-study comparability and robust evaluation of therapeutic efficacy. We optimized culture conditions for SVF expansion under GMP-compatible settings. Among the media tested, HEM demonstrated superior capacity to expand EC and FAP without altering key marker profiles. These findings support the selection of HEM as a preferred medium for clinical-grade SVF expansion and contribute to reproducibility and translational readiness. We compared adipose tissue harvesting methods and demonstrated that lipoaspirate-derived SVF is phenotypically comparable to en bloc derived SVF in terms of EC and FAP cells. Given its

PROMOS

reduced invasiveness, better scalability, and compatibility with closed systems, lipoaspiration represents a clinically feasible and ethically favorable approach for autologous applications. In addition, multiparametric flow cytometry profiling of 59 donors revealed that SVF composition is influenced by patient-specific variables such as age and weight loss history. These data suggest that donor characteristics may modulate the regenerative potential of ASC subsets, particularly pro-angiogenic and CD26⁺/CD55⁺ populations, reinforcing the concept of donor stratification in future therapeutic protocols. We further examined the cells expansion and cryopreservation. While expansion induces known shifts in surface marker expression (e.g., reduction of CD34), essential mesenchymal characteristics are largely retained. Cryopreservation, including long-term storage, preserves viability and functional potential when controlled protocols are applied, supporting the feasibility of SVF biobanking within PROMOS. Collectively, Deliverable 2 establishes a standardized, evidence-based platform for wound evaluation and SVF characterization that strengthens the translational potential of SVF-based regenerative therapies.

Building on these findings, several strategic directions emerge for future clinical translation:

1. **Marker-guided cell selection**

The identification of functionally enriched ASC subpopulations (e.g., CD55⁺CD26⁺, CD31⁺CD146⁺) opens the possibility of refining SVF-based products through marker-guided enrichment strategies. Future work should integrate high-resolution phenotyping with functional in vitro and in vivo assays to define predictive biomarker signatures of regenerative efficacy.

2. **Donor stratification and personalized regenerative medicine**

The observed correlations between donor characteristics and SVF composition suggest that patient profiling may optimize therapeutic outcomes. Developing predictive algorithms that incorporate age, BMI, metabolic status, and ASC subtype distribution could enable personalized cell therapy approaches.

3. **Standardization toward clinical trials**

The methodological harmonization achieved in this deliverable provides a foundation for regulatory alignment and multicenter reproducibility. Future efforts should focus on establishing SOPs for GMP manufacturing, quality control release criteria, and potency assays tailored to wound healing endpoints.

PROMOS

4. Integration with advanced wound monitoring technologies

Combining SVF therapy with quantitative biophysical monitoring tools may allow real-time assessment of treatment response and early identification of non-responders. This integrated approach could enhance adaptive trial design and improve therapeutic precision.

5. Long-term biobanking and repeat treatments

The confirmation that cryopreserved SVF retains therapeutic properties supports the development of structured SVF biobanks. This strategy may enable staged or repeated administrations, particularly in chronic wound patients at high risk of recurrence.

6. Mechanistic insights and microenvironment modulation

Future research should further dissect the molecular mechanisms linking surface marker expression to functional output, particularly in relation to complement regulation, angiogenesis, immune modulation, and extracellular matrix remodeling within the wound niche.

Deliverable 2 significantly advances the methodological standardization, biological understanding, and translational readiness of SVF-based regenerative therapies within PROMOS. By integrating rigorous wound assessment tools with refined cellular characterization and optimized processing workflows, PROMOS is positioned to move from experimental standardization toward clinically actionable regenerative strategies for chronic wound management.

References

1. Masson-Meyers, D. S., Andrade, T. A. M., Caetano, G. F., et al. (2020). Experimental models and methods for cutaneous wound healing assessment. *International Journal of Experimental Pathology*, 101(1–2), 21–37.
2. Koschwanez, H. E., & Broadbent, E. (2011). The use of wound healing assessment methods in psychological studies: A review and recommendations. *British Journal of Health Psychology*, 16(1), 1–32.

PROMOS

3. Stotts, N. A., Rodeheaver, G. T., Thomas, D. R., et al. (2001). An instrument to measure healing in pressure ulcers: Development and validation of the Pressure Ulcer Scale for Healing (PUSH). *Journal of Gerontology: Biological Sciences and Medical Sciences*, 56(12), M795–M799.
4. Thomas, D. R., Goode, P. S., Tarquine, P. H., & Allman, R. M. (1997). Pressure Ulcer Scale for Healing (PUSH): Development and validation. *Journal of Gerontology: Biological Sciences and Medical Sciences*, 52(5), M370–M374.
5. Snyder, R. J., Cardinal, M., & Dauphinée, D. M. (2005). Reliability and validity of the Pressure Ulcer Scale for Healing. *Ostomy Wound Management*, 51(4), 24–30.
6. Harris, C., Bates-Jensen, B., Parslow, N., Raizman, R., Singh, M., & Ketchen, R. (2010). Bates-Jensen Wound Assessment Tool: Pictorial guide validation project. *Journal of Wound, Ostomy and Continence Nursing*, 37(3), 253–259.
7. Bates-Jensen, B. M., McCreath, H. E., Harputlu, D., & Patlan, A. (2019). Reliability of the Bates-Jensen Wound Assessment Tool for pressure injury assessment: The pressure ulcer detection study. *Wound Repair and Regeneration*, 27(4), 386–395.
8. Whitney, J. D., Bergquist-Beringer, S., McCormack, B., et al. (2003). Reliability and validity of the Bates-Jensen Wound Assessment Tool. *Journal of Wound, Ostomy and Continence Nursing*, 30(6), 303–308.
9. Varnado, L., Templin, T. N., et al. (2018). Feasibility and inter-rater reliability of the Bates-Jensen Wound Assessment Tool in long-term care. *Journal of Wound Care*, 27(7), 400–409.
10. Bates-Jensen, B. M. (2001). *The Bates-Jensen Wound Assessment Tool: User manual*.
11. Baharvand, M., et al. (2014). Cross-cultural adaptation and psychometric evaluation of the BWAT. *International Wound Journal*, 11(2), 128–134.
12. Jalilian, M., & Shiri, S. (2022). The reliability of the Wagner Scale for evaluation of diabetic wounds: A literature review. *Diabetes & Metabolic Syndrome*, 16(1), 102369.
13. Oyibo, S. O., Jude, E. B., Tarawneh, I., Nguyen, H. C., Harkless, L. B., & Boulton, A. J. (2001). A comparison of two diabetic foot ulcer classification systems: The Wagner and the University of Texas wound classification systems. *Diabetes Care*, 24(1), 84–88.
14. Monteiro-Soares, M., Martins-Mendes, D., Vaz-Carneiro, A., Sampaio, S., & Dinis-Ribeiro, M. (2014). Classification systems for lower extremity amputation prediction in subjects with active diabetic foot ulcer: A systematic review and meta-analysis. *Diabetes/Metabolism Research and Reviews*, 30(7), 610–622.
15. Treece, K. A., Macfarlane, R. M., Pound, N., Game, F. L., & Jeffcoate, W. J. (2004). Validation of a system of foot ulcer classification in diabetes mellitus. *Diabetic Medicine*, 21(9), 987–991.
16. Parisi, M. C., Zantut-Wittmann, D. E., Pavin, E. J., Machado, H., Nery, M., & Jeffcoate, W. J. (2008). Comparison of three systems of classification in predicting the outcome of diabetic foot ulcers in a Brazilian population. *European Journal of Endocrinology*, 159(4), 417–422.

PROMOS

17. Forsythe, R. O., Ozdemir, B. A., Chemla, E. S., Jones, K. G., & Hinchliffe, R. J. (2016). Interobserver reliability of three validated scoring systems in the assessment of diabetic foot ulcers. *International Journal of Lower Extremity Wounds*, 15, 213–219.
18. Abbas, Z. G., Lutale, J. K., Game, F. L., & Jeffcoate, W. J. (2008). Comparison of four systems of classification of diabetic foot ulcers in Tanzania. *Diabetic Medicine*, 25(2), 134–137.
19. Greaves, N. S., Benatar, B., Whiteside, S., Alonso-Rasgado, T., Baguneid, M., & Bayat, A. (2014). Optical coherence tomography: A reliable alternative to invasive histological assessment of acute wound healing in human skin? *British Journal of Dermatology*, 170(4), 840–850.
20. Bharara, M., Schoess, J., Nouvong, A., & Armstrong, D. G. (2010). Wound inflammatory index: A “proof of concept” study to assess wound healing trajectory. *Journal of Diabetes Science and Technology*, 4(4), 773–779.
21. Weingarten, M. S., Samuels, J. A., Neidrauer, M., Mao, X., Diaz, D., McGuire, J., ... & Papazoglou, E. S. (2012). Diffuse near-infrared spectroscopy prediction of healing in diabetic foot ulcers: a human study and cost analysis. *Wound Repair and Regeneration*, 20(6), 911-917.
22. Antoszewska, M., Połomska, K., Spychalski, P., Kekonen, A., Viik, J., & Barańska-Rybak, W. (2025). Bioimpedance Measurement for Monitoring Chronic Wounds: A Systematic Review. *International Wound Journal*, 22(6), e70707.
23. Bharara, M., Schoess, J., Nouvong, A., & Armstrong, D. G. (2010). Wound inflammatory index: a “proof of concept” study to assess wound healing trajectory.
24. Coleman, W. P., III. (1999). Fat transplantation. *Dermatologic Clinics*, 17(4), 891–viii.
25. Hanke, C., & Dent, M. (2021). Tumescence anesthesia: A brief history regarding the evolution of tumescent solution. *Journal of Drugs in Dermatology*, 20(12), 1283–1287.
26. Katz, B. E., Bruck, M. C., & Coleman, W. P., III. (2001). The benefits of powered liposuction versus traditional liposuction: A paired comparison analysis. *Dermatologic Surgery*, 27(10), 863–867.
27. Keck, M., Kober, J., Riedl, O., Kitzinger, H. B., Wolf, S., Stulnig, T. M., Zeyda, M., & Gugerell, A. (2014). Power assisted liposuction to obtain adipose-derived stem cells: Impact on viability and differentiation to adipocytes in comparison to manual aspiration. *Journal of Plastic, Reconstructive & Aesthetic Surgery*, 67(1), e1–e8.
28. Gerth, D. J., King, B., Rabach, L., Glasgold, R. A., & Glasgold, M. J. (2014). Long-term volumetric retention of autologous fat grafting processed with closed-membrane filtration. *Aesthetic Surgery Journal*, 34(7), 985-994.
29. Sabol, R. A., Bowles, A. C., Côté, A., Wise, R., Pashos, N., & Bunnell, B. A. (2018). Therapeutic potential of adipose stem cells. *Cell Biology and Translational Medicine*, Volume 13: Stem Cells in Development and Disease, 15-25.
30. Emont, M. P., Jacobs, C., Essene, A. L., Pant, D., Tenen, D., Colleluori, G., ... & Rosen, E. D. (2022). A single-cell atlas of human and mouse white adipose tissue. *Nature*, 603(7903), 926-933.

PROMOS

31. Rennert, R. C., Januszyk, M., Sorkin, M., Rodrigues, M., Maan, Z. N., Duscher, D., ... & Paik, K. Microfluidic single-cell transcriptional analysis rationally identifies novel surface marker profiles to enhance cell-based therapies. *Nat Commun* 2016; 7: 11945-11954.
32. Barrera, J. A., Trotsyuk, A. A., Maan, Z. N., Bonham, C. A., Larson, M. R., Mittermiller, P. A., ... & Gurtner, G. C. (2021). Adipose-derived stromal cells seeded in pullulan-collagen hydrogels improve healing in murine burns. *Tissue Engineering Part A*, 27(11-12), 844-856.
33. Wu, S. C. M., Zhu, M., Chik, S. C., Kwok, M., Javed, A., Law, L., ... & Poon, E. N. Y. (2023). Adipose tissue-derived human mesenchymal stromal cells can better suppress complement lysis, engraft and inhibit acute graft-versus-host disease in mice. *Stem Cell Research & Therapy*, 14(1), 167.
34. Jiang, Y., Yao, Y., Li, J., Wang, Y., Cheng, J., & Zhu, Y. (2021). Functional dissection of CD26 and its pharmacological inhibition by sitagliptin during skin wound healing. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, 27, e928933-1.
35. Baticic Pucar, L., Pernjak Pugel, E., Detel, D., & Varljen, J. (2017). Involvement of DPP IV/CD26 in cutaneous wound healing process in mice. *Wound repair and regeneration*, 25(1), 25-40.
36. Walmsley, G. G., Atashroo, D. A., Maan, Z. N., Hu, M. S., Zielins, E. R., Tsai, J. M., ... & Longaker, M. T. (2015). High-throughput screening of surface marker expression on undifferentiated and differentiated human adipose-derived stromal cells. *Tissue Engineering Part A*, 21(15-16), 2281-2291.
37. Hatzmann, F. M., Großmann, S., Waldegger, P., Wieggers, G. J., Mandl, M., Rauchenwald, T., ... & Zwerschke, W. (2022). Dipeptidyl peptidase-4 cell surface expression marks an abundant adipose stem/progenitor cell population with high stemness in human white adipose tissue. *Adipocyte*, 11(1), 601-615.
38. Psaroudis, R. T., Singh, U., Lora, M., Jeon, P., Boursiquot, A., Stochaj, U., ... & Colmegna, I. (2022). CD26 is a senescence marker associated with reduced immunopotency of human adipose tissue-derived multipotent mesenchymal stromal cells. *Stem Cell Research & Therapy*, 13(1), 358.
39. Tang, Y., Xu, Z. Y., Song, S. S., Song, Y. J., Yang, L. J., Wang, L., ... & Yin, F. (2025). Obesity hinders the efficacy of adipose-derived stem cells for knee osteoarthritis by reducing the proportion of DPP4+ stem cells. *Stem Cells Translational Medicine*, 14(8), szaf004.
40. Marcelin, G., Ferreira, A., Liu, Y., Atlan, M., Aron-Wisnewsky, J., Pelloux, V., ... & Clément, K. (2017). A PDGFR α -mediated switch toward CD9^{high} adipocyte progenitors controls obesity-induced adipose tissue fibrosis. *Cell metabolism*, 25(3), 673-685.
41. Vuerich, R., Groppa, E., Vodret, S., Ring, N. A. R., Stocco, C., Bossi, F., ... & Zacchigna, S. (2023). Ischemic wound revascularization by the stromal vascular fraction relies on host-donor hybrid vessels. *NPJ Regenerative Medicine*, 8(1), 8.
42. Durandt, C., Dessels, C., Da Silva, C., Murdoch, C., & Pepper, M. S. (2019). The effect of early rounds of ex vivo expansion and cryopreservation on the adipogenic differentiation capacity of adipose-derived stromal/stem cells. *Scientific Reports*, 9(1), 15943.

PROMOS

43. Inafuku, N., Sowa, Y., Kishida, T., Sawai, S., Ntege, E. H., Numajiri, T., ... & Mazda, O. (2025). Investigation of the stemness and wound-healing potential of long-term cryopreserved stromal vascular fraction cells. *Regenerative Therapy*, 29, 128-139.
44. Zheng, W., Shen, J., Wang, H., Yin, Y., Wang, P., Jin, P., & Zhang, A. (2019). Effects of frozen stromal vascular fraction on the survival of cryopreserved fat tissue. *Aesthetic Plastic Surgery*, 43(3), 826-835.